Nexalin Technology IncNASDAQ NXL Stock Report

Nexalin Technology, Inc. designs and develops neurostimulation products. The company is headquartered in Laguna Niguel, California. The company went IPO on 2022-09-16. The firm has developed an easy-to-administer medical device, Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. The company is also designing clinical trials for the use of Gen-2 for the treatment of substance use disorders and particularly substance abuse issues related to opiates, chronic pain, Alzheimer’s disease and dementia. The firm's products are non-invasive and undetectable and can provide relief to those afflicted with mental health issues without adverse side effects. Its design of varying voltages, currents, electromagnetic fields and various frequencies called as waveform. The Company’s devices generate a high frequency, charge balanced electrical current waveform that is applied to an array of electrodes on the head.